Downregulation of high mobility group box 1 attenuates the severity of acute lung injury in endotoxemic mice

XIAOJUAN ZHANG, ZHENGANG LUAN, YINGJIAN LIANG, YINA LIU and XIAOCHUN MA

Intensive Care Unit, First Affiliated Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China

Received April 7, 2014; Accepted January 7, 2015

DOI: 10.3892/mmr.2015.3251

Abstract. High mobility group box 1 (HMGB1) is a systemic inflammation-associated cytokine mediator. The aim of the present study was to examine the effect of the downregulation of HMGB1 in a lipopolysaccharide (LPS)-induced mouse model of acute lung injury (ALI). It was identified that serum levels of tumor necrosis factor-α and interleukin-1β, lung myeloperoxidase activity and malondialdehyde content, as well as lung wet/dry weight ratios were all increased following LPS challenge. However, LPS-mediated increases in these parameters were significantly downregulated in HMGB1 small interfering (si)RNA-treated mice versus the negative control siRNA-treated mice. In addition, the administration of HMGB1 siRNA in LPS-treated mice resulted in a decreased DNA binding activity of nuclear factor-κB (NF-κB) in the lung. It was demonstrated that downregulation of HMGB1 decreases inflammation and the severity of sepsis associated with ALI, possibly via inhibiting the NF-κB DNA-binding activity. The present data support HMGB1 as a contributor to the pathogenesis of LPS-induced sepsis and ALI.

Introduction

Sepsis is associated with a high mortality rate (1,2). Acute lung injury (ALI) is characterized by an intense inflammatory process in the lung. It is the most common complication of severe sepsis as it is associated with the high rates of morbidity and mortality (3-7). Despite significant advances in understanding the pathogenesis and management of ALI in sepsis, the mortality rate remains high.

Lipopolysaccharide (LPS), the major endotoxin of gram-negative bacteria, may enter the bloodstream and elicit an acute systemic inflammatory response, which leads to sepsis and shock (8). Pro-inflammatory cytokines are involved in the development of tissue damage, metabolic acidosis, hypotension, multiple organ failure and even fatality during sepsis (9,10). High mobility group box 1 (HMGB1) is a cytokine mediator that has been observed to have an important role in delayed endotoxin lethality and systemic inflammation in murine sepsis models (11-14). HMGB1 is highly expressed in the nucleus of endothelial cells, which are a crucial source of HMGB1 in inflammation (15,16). As a pro-inflammatory cytokine, HMGB1 has been hypothesized to be an ideal target in sepsis therapy (17-21). There is clear evidence that anti-HMGB1 antibodies may protect against lethality, even if the first dose of antibody is administered 24 h after infection (22). A previous study has also identified chemically synthesized antisense oligonucleotides (23), which decrease HMGB1 expression and significantly inhibit inflammation in human umbilical vein endothelial cells (HUVECs). Therefore, gene transfer has been proposed as a novel method to produce cytokine inhibitors or antagonists to treat inflammation. However, the gene-silencing effects of HMGB1 via RNA interference (RNAi) in the development of ALI in sepsis remain to be elucidated. The aim of the present study was to determine whether the downregulation of HMGB1 reduced endotoxin-induced inflammation in mice.

Materials and methods

Animals. A total of 20 male C57BL/6 mice (age, 8-10 weeks) were obtained from the Experimental Animal Center of China Medical University (Shenyang, China). The mice were housed in rooms maintained at 20±2˚C in a 12 h light/dark cycle for at least 1 week to acclimate to their surroundings, during which mice had access to water and standard mouse chow ad libitum. The animal study protocol was approved by the Institutional Animal Care and Use Committee of China Medical University.

HMGB1 small interfering RNA (siRNA). siRNA sequences targeting the coding regions of human HMGB1 were generated using the siRNA design center from GenScript Co., Ltd. (Nanjing, China). The siRNA sequences were inserted into the pRNA-U6.1/Neo vector attained from GenScript. Recombinant siRNA plasmids were transfected into HUVECs and the expression of HMGB1 was verified using western blot analysis (23). In brief, in order to construct pRNAU6.1/Neo-HMGB1, the human HMGB1 siRNA
supernatants were then collected for biochemical analyses. MPO activity and MDA levels in the lung tissue were determined using commercially available kits (Jiancheng Bioengineering Institute, Nanjing, China). For the MPO activity assays, the supernatants were incubated with hydrogen peroxide in the presence of 0.167 mg/ml O-dianisidine dihydrochloride for 30 min. The change in absorbance at 460 nm for each sample was recorded with a plate reader (BioTek Instruments, Inc., Winooski, VT, USA). The MPO activity was defined as the quantity of enzyme degrading 1 µmol peroxide/min at 37°C and is expressed as units per gram lung tissue. The MDA content was determined based on the reaction of MDA with thiobarbituric acid (Sigma-Aldrich) at 90-100°C. The MDA levels are expressed as nmol/mg protein.

Electrophoretic mobility shift assay (EMSA). NF-κB DNA binding activity was measured with EMSA using nuclear extracts from lung tissue. Nuclear proteins were extracted using nuclear and cytoplasmic extraction reagent kits (Pierce Biotechnology, Rockford, IL, USA). End labeling of double-strand oligonucleotides containing the NF-κB consensus sequence (5'-AGTTGAGGGGACTTTCCCCAGG-3') was performed using γ-32P-dATP (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and T4-polynucleotide kinase (Takara Bio Inc., Ohtsu, Japan) at 37°C for 60 min. Nuclear extracts (20 µg) were incubated in a 20 µl reaction mixture of 4% glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, 10 mM Tris-HCl (pH 7.5) and 50 µg/ml poly(deoxyinosinic-deoxyctydilic) acid (P4929; Sigma-Aldrich), with or without unlabeled oligonucleotide for 10 min at room temperature. 32P-labeled oligonucleotide probes were then added and incubated at room temperature for 20 min. Electrophoresis of samples was performed on a 5% polyacrylamide gel and visualized directly by autoradiography following drying the gel. Quantification was performed by image analysis using densitometry (ChemiDoc system; Bio-Rad, Hercules, CA, USA).

Statistical analysis. The results are expressed as the mean ± standard deviation of at least three separate experiments. A one-way analysis of variance with Dunnett's multiple comparison tests was performed using SPSS software, version 10.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

Results

Downregulation of HMGB1 attenuates LPS-induced histopathological changes in lung tissue. To evaluate the histopathological characteristics of lung tissue in LPS-challenged mice, lung tissue sections were stained with H&E. As shown in Fig. 1A, lung tissue from the sham group exhibited a normal structure and no histopathological changes. In the LPS-treated mice with or without pRNA-U6.1/Neo-vector injection, the lungs had widespread increased alveolar wall thickness caused by edema, severe hemorrhage in the alveolus, alveolus collapse and marked inflammatory cell infiltration (Fig. 1B and C). However, in the HMGB1 siRNA and LPS-treated groups, histopathological changes in the lung were attenuated when compared with those in the LPS plus pRNA-U6.1/Neo-vector group, particularly the inflammatory cell infiltration findings (Fig. 1D). These results suggest that downregulation of HMGB1 may protect mice against LPS-induced lung injury.
Downregulation of HMGB1 reduces lung W/D ratio, MDA level and MPO activity in lung tissue of LPS-treated mice. The W/D ratio was used to evaluate pulmonary vascular permeability. When compared with the sham group, the lung W/D ratios were significantly increased in the LPS group and LPS plus pRNA-U6.1/Neo-vector-treated group. No difference was identified between the LPS and LPS plus pRNA-U6.1/Neo-vector-treated groups. However, the increased
lung W/D ratios in the LPS group were significantly reduced by treatment with HMGB1 siRNA (Fig. 2A; P<0.05), suggesting that downregulation of HMGB1 may prevent LPS-induced increases in lung vascular permeability. To assess neutrophil accumulation within pulmonary tissue, MPO activity was measured. Following LPS administration, MPO activity in lung tissue was significantly increased when compared with the control group. However, the increased MPO activity was markedly reduced following downregulation of HMGB1 (Fig. 2B; P<0.05). In addition, LPS administration significantly raised MDA levels in lung tissues and the increased MDA levels were suppressed by downregulating HMGB1 (Fig. 2C).

Downregulation of HMGB1 inhibits production of inflammatory cytokines in LPS-challenged mice. Inflammatory cytokines, such as TNF-α and IL-1β, are known to be involved in the pathophysiology of LPS-mediated pulmonary inflammation. Therefore, the serum levels of TNF-α and IL-1β were determined in LPS-challenged mice. As shown in Fig. 3, levels of serum TNF-α (Fig. 3A) and IL-1β (Fig. 3B) were minimally expressed in the control group. However, LPS administration markedly increased the expression of serum TNF-α and IL-1β levels, which were significantly attenuated following downregulation of HMGB1. These findings indicated that downregulation of HMGB1 inhibits LPS-induced production of inflammatory cytokines.

Downregulation of HMGB1 inhibits LPS-induced activation of NF-κB. The NF-κB DNA binding activity in the lung tissue samples was determined. The NF-κB DNA binding activity in the lung tissue of LPS-treated mice with or without negative control siRNA injection was increased when compared with that of the control group. By contrast, HMGB1 knockdown decreased LPS-induced increases in NF-κB DNA binding activity when compared with the LPS plus pRNAU6.1/Neo-vector group (Fig. 4; P<0.05).

Discussion

In the present study, the effects of HMGB1 downregulation were investigated in LPS-induced ALI in mice. It was observed that HMGB1 siRNA-treated animals had a decreased lung W/D ratio compared with the negative control siRNA-treated mice. It is well-established that the overproduction of pro-inflammatory cytokines promotes the development of sepsis (25). Among these pro-inflammatory cytokines, TNF-α
and IL-1β, which are released within minutes after endotoxin exposure, are the most important early response cytokines. Previous studies have indicated that the persistent elevation of pro-inflammatory cytokines is associated with a worse outcome in patients with sepsis (26). In the present study, it was demonstrated that the serum concentrations of TNF-α and IL-1β increased significantly following LPS administration. However, these changes were markedly inhibited by HMGB1 siRNA treatment. In addition, using pRNA-U6.1/Neo-HMGB1 treatment significantly improved pulmonary histopathological findings and attenuated the severity of lung vascular permeability and edema.

NF-κB is a universal transcription factor that has a crucial role in regulating the transcription of over 200 genes, a number of which have important roles in the development of septic shock (27), including TNF-α and IL-1 (28). In the present study, it was identified that the downregulation of HMGB1 may inhibit the activation of NF-κB and consequently downregulate downstream inflammatory cytokines, relieve endothelial permeability and attenuate LPS-associated ALI in septic mice.

In conclusion, it was demonstrated that the downregulation of HMGB1 may inhibit LPS-induced inflammation and ALI, suggesting that it may provide a novel therapeutic strategy for sepsis.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China (grant no. 81301619) and Shenyang Science and Technology plan projects (grant no. F13-220-9-11).

References